2 Sources
[1]
Study shows AI can predict prognosis in triple-negative breast cancer
Karolinska InstituteNov 19 2024 Researchers at Karolinska Institutet in Sweden have investigated how well different AI models can predict the prognosis of triple-negative breast cancer by analyzing certain immune cells inside the tumor. The study, published in the journal eClinicalMedicine, is an important step towards using AI in cancer care to improve patient health. Tumour-infiltrating lymphocytes are a type of immune cell that plays an important role in fighting cancer. When they are present in a tumor, it means that the immune system is trying to attack and destroy the cancer cells. These immune cells can be important in predicting how a patient with so-called triple-negative breast cancer will respond to treatment and how the disease will progress. But when pathologists assess the immune cells, the results can vary. Artificial intelligence (AI) can help standardise and automate this process, but it has been difficult to demonstrate that AI works well enough to be used in healthcare. Compared ten AI models The researchers tested ten different AI models and compared their ability to analyze tumor-infiltrating lymphocytes in triple-negative breast cancer tissue samples. The results showed that the AI models varied in their analytical performance. Despite these differences, eight of the ten models showed good prognostic ability, meaning they were able to predict patients' future health in a similar way. Even models trained on fewer samples showed good prognostic ability, suggesting that tumor-infiltrating lymphocytes are a robust biomarker." Balazs Acs, researcher at the Department of Oncology-Pathology, Karolinska Institutet Independent studies needed The study shows that large datasets are needed to compare different AI tools and ensure that they work well before they can be used in healthcare. While the results are promising, more validation is needed. "Our research highlights the importance of independent studies that mimic real clinical practice," says Balazs Acs. "Only through such testing can we ensure that AI tools are reliable and effective for clinical use." Karolinska Institute Journal reference: Vidal, J. M., et al. (2024). The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably? eClinicalMedicine. doi.org/10.1016/j.eclinm.2024.102928.
[2]
AI analysis of immune cells can predict breast cancer prognosis
Researchers at Karolinska Institutet have investigated how well different AI models can predict the prognosis of triple-negative breast cancer by analyzing certain immune cells inside the tumor. The study, published in the journal eClinicalMedicine, is an important step toward using AI in cancer care to improve patient health. Tumor-infiltrating lymphocytes are a type of immune cell that plays an important role in fighting cancer. When they are present in a tumor, it means that the immune system is trying to attack and destroy the cancer cells. These immune cells can be important in predicting how a patient with so-called triple-negative breast cancer will respond to treatment and how the disease will progress. But when pathologists assess the immune cells, the results can vary. Artificial intelligence (AI) can help standardize and automate this process, but it has been difficult to demonstrate that AI works well enough to be used in health care. The researchers tested 10 AI models and compared their ability to analyze tumor-infiltrating lymphocytes in triple-negative breast cancer tissue samples. The results showed that the AI models varied in their analytical performance. Despite these differences, eight of the ten models showed good prognostic ability, meaning they were able to predict patients' future health in a similar way. "Even models trained on fewer samples showed good prognostic ability, suggesting that tumor-infiltrating lymphocytes are a robust biomarker," says Balazs Acs, researcher at the Department of Oncology-Pathology, Karolinska Institutet. Independent studies needed The study shows that large datasets are needed to compare different AI tools and ensure that they work well before they can be used in health care. While the results are promising, more validation is needed. "Our research highlights the importance of independent studies that mimic real clinical practice," says Acs. "Only through such testing can we ensure that AI tools are reliable and effective for clinical use."
Share
Copy Link
A study by Karolinska Institutet researchers demonstrates that AI models can effectively analyze tumor-infiltrating lymphocytes to predict outcomes in triple-negative breast cancer, marking a significant step towards AI integration in cancer care.
Researchers at Karolinska Institutet in Sweden have made significant strides in applying artificial intelligence (AI) to predict the prognosis of triple-negative breast cancer. The study, published in the journal eClinicalMedicine, focused on the analysis of tumor-infiltrating lymphocytes (TILs) using various AI models, potentially paving the way for more accurate and standardized cancer prognosis 12.
Tumor-infiltrating lymphocytes are crucial immune cells that play a vital role in combating cancer. Their presence within a tumor indicates an active immune response against cancer cells. In triple-negative breast cancer, these lymphocytes serve as important indicators of treatment response and disease progression 1.
While TILs are valuable prognostic markers, their assessment by pathologists can be subjective and variable. This inconsistency poses a challenge in clinical settings. AI offers a promising solution by potentially standardizing and automating the analysis process, though proving its efficacy for healthcare application has been challenging 2.
The research team evaluated ten different AI models, comparing their ability to analyze TILs in triple-negative breast cancer tissue samples. Key findings include:
Balazs Acs, a researcher at the Department of Oncology-Pathology, Karolinska Institutet, noted, "Even models trained on fewer samples showed good prognostic ability, suggesting that tumor-infiltrating lymphocytes are a robust biomarker" 2.
This study represents a significant step towards integrating AI into cancer care for improved patient outcomes. However, the researchers emphasize the need for further validation:
"Our research highlights the importance of independent studies that mimic real clinical practice," Acs stated, underlining the need for thorough testing to ensure the clinical viability of AI tools 2.
As the field progresses, this research opens new avenues for AI application in cancer diagnostics and prognostics, potentially leading to more personalized and effective treatment strategies for patients with triple-negative breast cancer.
Summarized by
Navi
[2]
NVIDIA announces significant upgrades to its GeForce NOW cloud gaming service, including RTX 5080-class performance, improved streaming quality, and an expanded game library, set to launch in September 2025.
9 Sources
Technology
16 hrs ago
9 Sources
Technology
16 hrs ago
Google's Made by Google 2025 event showcases the Pixel 10 series, featuring advanced AI capabilities, improved hardware, and ecosystem integrations. The launch includes new smartphones, wearables, and AI-driven features, positioning Google as a strong competitor in the premium device market.
4 Sources
Technology
16 hrs ago
4 Sources
Technology
16 hrs ago
Palo Alto Networks reports impressive Q4 results and forecasts robust growth for fiscal 2026, driven by AI-powered cybersecurity solutions and the strategic acquisition of CyberArk.
6 Sources
Technology
16 hrs ago
6 Sources
Technology
16 hrs ago
OpenAI updates GPT-5 to make it more approachable following user feedback, sparking debate about AI personality and user preferences.
6 Sources
Technology
1 day ago
6 Sources
Technology
1 day ago
President Trump's plan to deregulate AI development in the US faces a significant challenge from the European Union's comprehensive AI regulations, which could influence global standards and affect American tech companies' operations worldwide.
2 Sources
Policy
8 hrs ago
2 Sources
Policy
8 hrs ago